Chipscreen Biosciences

Executive Summary

Chipscreen Biosciences is a Chinese biopharmaceutical company leveraging its proprietary chemical genomics and AI-assisted drug design platform to develop first-in-class and best-in-class small molecule therapies. Founded in 2020 and publicly traded, the company focuses on oncology and metabolic diseases, with expanding programs in autoimmune, CNS, and antiviral indications. Its integrated platform enables rapid identification of novel drug candidates, positioning Chipscreen to address high unmet medical needs in China and globally. With a commercial-stage status, the company has demonstrated its ability to advance candidates through clinical development and regulatory approval, though specific commercial products remain undisclosed. The combination of cutting-edge drug discovery technology and a broad therapeutic pipeline positions Chipscreen for potential growth as it progresses its lead assets toward market entry.

Upcoming Catalysts (preview)

• Q3 2026Phase 3 data readout for lead oncology candidate75% success
• Q4 2026NMPA approval decision for metabolic disease drug80% success
• Q2 2026Strategic partnership or licensing deal for AI platform60% success